Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLostes Bardaji, M Julia
dc.contributor.authorGarcía Illescas, David
dc.contributor.authorValverde Morales, Claudia Maria
dc.contributor.authorSerrano Garcia, César
dc.date.accessioned2022-03-11T12:18:57Z
dc.date.available2022-03-11T12:18:57Z
dc.date.issued2021-01
dc.identifier.citationLostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan;13:1-12.
dc.identifier.issn1758-8359
dc.identifier.urihttp://hdl.handle.net/11351/7143
dc.descriptionRipretinib; Sarcoma; Tyrosine kinase inhibitor
dc.description.abstractGastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST patients. This is the result of continuous, deep understanding of KIT and PDGFRA GIST oncogenic drivers as well as the resistance mechanisms associated to tumor progression. However, the complexity of GIST molecular heterogeneity is an evolving field, and critical questions remain open. Specifically, the clinical benefit of approved and/or investigated targeted agents is strikingly modest at advanced stages of the disease when compared with the activity of first-line imatinib. Ripretinib is a novel switch-pocket inhibitor with broad activity against KIT and PDGFRA oncoproteins and has recently demonstrated antitumoral activity across phase I to phase III clinical trials. Therefore, ripretinib has emerged as a new standard of care for advanced, multi-resistant GIST patients. Based on this data, the Food and Drug Administration has granted in 2020 the approval of ripretinib for GIST patients after progression to imatinib, sunitinib and regorafenib. This, in turn, constitutes a major breakthrough in sarcoma drug development, as there have not been new treatment approvals in GIST for nearly a decade. Herein, we provide a critical review on the preclinical and clinical development of ripretinib in GIST. Furthermore, we seek to assess the biological and clinical impact of this new standard of care on the course of the disease, aiming to provide an insight on future treatments strategies for the next coming years.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesTherapeutic Advances in Medical Oncology;13
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectTracte gastrointestinal - Càncer - Tractament
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshGastrointestinal Stromal Tumors
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents
dc.subject.mesh/therapeutic use
dc.titleRipretinib in gastrointestinal stromal tumor: the long-awaited step forward
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/1758835920986498
dc.subject.decstumores del estroma gastrointestinal
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.1177/1758835920986498
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lostes-Bardaji MJ, García-Illescas D, Valverde C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Serrano C] Sarcoma Translational Research Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid33473249
dc.identifier.wos000610180700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record